Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence for upper tract urothelial carcinoma after radical nephroureterectomy
This article relates to:
-
Editorial Comment on Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence for upper tract urothelial carcinoma after radical nephroureterectomy
- Volume 31Issue 4International Journal of Urology
- pages: 418-419
- First Published online: February 1, 2024
-
Letter to the Editor Re: Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence upper tract urothelial carcinoma after radical nephroureterectomy
- Volume 31Issue 4International Journal of Urology
- pages: 420-420
- First Published online: January 29, 2024
-
Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence upper tract urothelial carcinoma after radical nephroureterectomy
- Volume 31Issue 4International Journal of Urology
- pages: 421-421
- First Published online: April 3, 2024
Tsung Yu Yu
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University and College of Medicine, Kaohsiung, Taiwan
Search for more papers by this authorHung Jen Wang
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University and College of Medicine, Kaohsiung, Taiwan
Search for more papers by this authorMin Tse Sung
Department of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
Search for more papers by this authorYao Chi Chuang
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University and College of Medicine, Kaohsiung, Taiwan
Center for Shockwave Medicine and Tissue Engineering, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
Search for more papers by this authorYen Ta Chen
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University and College of Medicine, Kaohsiung, Taiwan
Search for more papers by this authorYuan Tso Cheng
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University and College of Medicine, Kaohsiung, Taiwan
Search for more papers by this authorChih Hsiung Kang
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University and College of Medicine, Kaohsiung, Taiwan
Search for more papers by this authorHui Ying Liu
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University and College of Medicine, Kaohsiung, Taiwan
Search for more papers by this authorYin Lun Chang
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University and College of Medicine, Kaohsiung, Taiwan
Search for more papers by this authorCorresponding Author
Hao Lun Luo
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University and College of Medicine, Kaohsiung, Taiwan
Center for Shockwave Medicine and Tissue Engineering, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
Correspondence
Hao Lun Luo, Department of Urology, Kaohsiung Chang Gung Memorial Hospital, 123, Ta-Pei Road, Niaosung, Kaohsiung, Taiwan.
Email: [email protected]
Search for more papers by this authorTsung Yu Yu
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University and College of Medicine, Kaohsiung, Taiwan
Search for more papers by this authorHung Jen Wang
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University and College of Medicine, Kaohsiung, Taiwan
Search for more papers by this authorMin Tse Sung
Department of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
Search for more papers by this authorYao Chi Chuang
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University and College of Medicine, Kaohsiung, Taiwan
Center for Shockwave Medicine and Tissue Engineering, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
Search for more papers by this authorYen Ta Chen
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University and College of Medicine, Kaohsiung, Taiwan
Search for more papers by this authorYuan Tso Cheng
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University and College of Medicine, Kaohsiung, Taiwan
Search for more papers by this authorChih Hsiung Kang
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University and College of Medicine, Kaohsiung, Taiwan
Search for more papers by this authorHui Ying Liu
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University and College of Medicine, Kaohsiung, Taiwan
Search for more papers by this authorYin Lun Chang
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University and College of Medicine, Kaohsiung, Taiwan
Search for more papers by this authorCorresponding Author
Hao Lun Luo
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University and College of Medicine, Kaohsiung, Taiwan
Center for Shockwave Medicine and Tissue Engineering, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
Correspondence
Hao Lun Luo, Department of Urology, Kaohsiung Chang Gung Memorial Hospital, 123, Ta-Pei Road, Niaosung, Kaohsiung, Taiwan.
Email: [email protected]
Search for more papers by this authorAbstract
Purpose
To investigate the prognostic impact of variant histology (VH) on oncological outcomes in patients with upper urinary tract urothelial carcinoma (UTUC) who had undergone radical nephroureterectomy (RNU).
Patients and methods
A total of 1239 patients with clinically localized UTUC who underwent RNU at a single institution between January 2005 and June 2020 were included. The VH was reviewed by a uro-pathologist at our institution. The Cox regression model was used to perform multivariate analysis, including VH and other established prognostic factors for post-RNU oncological outcomes (intravesical recurrence [IVR], non-urothelial recurrence, and cancer-specific death).
Results
Of the 1239 patients with UTUC, 384 patients (31%) were found to have VH. Advanced tumor stage, lymph node metastasis, high tumor grade, lymphovascular invasion, open surgery, and renal pelvis had a significantly larger proportion of UTUC with VH compared to pure UTUC (all p < 0.05). VH was an independent prognostic factor associated with less IVR identified by multivariate analysis, more non-urothelial recurrence, and more cancer-specific mortality.
Conclusion
Patients with VH account for 31% with UTUC treated with RNU in this cohort. VH was an independent prognostic factor associated with more non-urothelial recurrence and cancer-specific mortality but less IVR.
CONFLICT OF INTEREST STATEMENT
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supporting Information
| Filename | Description |
|---|---|
| iju15376-sup-0001-TableS1.docxWord 2007 document , 15 KB | Table S1. |
| iju15376-sup-0002-TableS2.docxWord 2007 document , 14.9 KB | Table S2. |
| iju15376-sup-0003-TableS3.docxWord 2007 document , 18.5 KB | Table S3. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Rouprêt M, Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol. 2021; 79: 62–79.
- 2Abouassaly R, Alibhai SMH, Shah N, Timilshina N, Fleshner N, Finelli A. Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology. 2010; 76: 895–901.
- 3Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol. 2012; 62: 100–114.
- 4Sakano S, Matsuyama H, Kamiryo Y, Hayashida S, Yamamoto N, Kaneda Y, et al. Risk group stratification based on preoperative factors to predict survival after nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Ann Surg Oncol. 2013; 20: 4389–4396.
- 5Rink M, Robinson BD, Green DA, Cha EK, Hansen J, Comploj E, et al. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. J Urol. 2012; 188: 398–404.
- 6Kim JK, Moon KC, Jeong CW, Kwak C, Kim HH, Ku JH. Variant histology as a significant predictor of survival after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Urol Oncol. 2017; 35: 458.e9–458.e15.
- 7Chung HS, Hwang EC, Kim MS, Yu SH, Jung SI, Kang TW, et al. Effects of variant histology on the oncologic outcomes of patients with upper urinary tract carcinoma after radical nephroureterectomy: a propensity score-matched analysis. Clin Genitourin Cancer. 2019; 17: e394–e407.
- 8Deuker M, Stolzenbach LF, Collà Ruvolo C, Nocera L, Tian Z, Roos FC, et al. Upper urinary tract tumors: variant histology versus urothelial carcinoma. Clin Genitourin Cancer. 2021; 19: 117–124.
- 9Luo HL, Ohyama C, Hatakeyama S, Wang HJ, Yoneyama T, Yang WC, et al. Unusual presentation of upper urinary tract urothelial carcinoma in Taiwan: direct comparison from Taiwan-Japan UTUC collaboration cohort: Taiwan-Japan UTUC comparison. Int J Urol. 2020; 27: 327–332.
- 10Lobo N, Shariat SF, Guo CC, Fernandez MI, Kassouf W, Choudhury A, et al. What is the significance of variant histology in urothelial carcinoma? Eur Urol Focus. 2020; 6: 653–663.
- 11Deuker M, Martin T, Stolzenbach F, Rosiello G, Collà Ruvolo C, Nocera L, et al. Bladder cancer: a comparison between non-urothelial variant histology and urothelial carcinoma across all stages and treatment modalities. Clin Genitourin Cancer. 2021; 19: 60–68.
- 12Yu J, Li G, Wang A, Luo Q, Liu Z, Niu Y, et al. Impact of squamous differentiation on intravesical recurrence and prognosis of patients with upper tract urothelial carcinoma. Ann Transl Med. 2019; 7: 377.
- 13Hashimoto T, Nakashima J, Kashima T, Hirasawa Y, Shimodaira K, Gondo T, et al. Clinical significance of preoperative renal function and gross hematuria for intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. Int J Urol. 2017; 24: 111–116.
- 14Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and Genetics of tumours of the Urinary System and Male Genital Organs, World Health Organisation Classification of Tumours. Lyon: IARCC Press; 2004.
- 15Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016; 70: 106–119.
- 16Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M, et al. Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol. 2013; 189: 1214–1221.
- 17De Lorenzis E, Albo G, Longo F, Bebi C, Boeri L, Montanari E. Current knowledge on genomic profiling of upper tract urothelial carcinoma. Genes. 2021; 12: 333.
- 18Hsieh MC, Sung MT, Chiang PH, Huang CH, Tang Y, Su YL. The prognostic impact of histopathological variants in patients with advanced urothelial carcinoma. PLoS One. 2015; 10:e0129268.
- 19Kaag MG, O'Malley RL, O'Malley P, Godoy G, Chen M, Smaldone MC, et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol. 2010; 58: 581–587.
- 20Kim M, Kim JK, Lee J, Kim YS, Lee JL, Kwak C, et al. Adjuvant treatments for advanced stage, non-metastatic upper tract urothelial carcinoma: a multicenter study. Int J Radiat Oncol Biol Phys. 2019; 104: 819–827.
- 21Luo HL, Chen TS, Wu WJ. The cancer behavior and current treatment strategy for upper urinary tract cancer. Urol Sci. 2022; 33: 161–169.
- 22Li C-E, Chien C-S, Chuang Y-C, Chang Y-I, Tang H-P, Kang C-H. Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer. Int Urol Nephrol. 2016; 48: 993–999.
- 23Chang C-H, Yang C-M, Yang A-H. Renal diagnosis of chronic hemodialysis patients with urinary tract transitional cell carcinoma in Taiwan. Cancer. 2007; 109: 1487–1492.
- 24Kusuda Y, Miyake H, Terakawa T, Kondo Y, Miura T, Fujisawa M. Gender as a significant predictor of intravesical recurrence in patients with urothelial carcinoma of the upper urinary tract following nephroureterectomy. Urol Oncol. 2013; 31: 899–903.
- 25Miyamoto H, Yang Z, Chen Y-T, Ishiguro H, Uemura H, Kubota Y, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007; 99: 558–568.
- 26Mbeutcha A, Rouprêt M, Kamat AM, Karakiewicz PI, Lawrentschuk N, Novara G, et al. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World J Urol. 2017; 35: 337–353.
- 27Kang CH, Yu TJ, Hsieh HH, Yang JW, Shu K, Huang CC, et al. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer. 2003; 98: 1620–1626.
- 28Seiler R, Ashab HA, Erho N, van Rhijn BW, Winters B, Douglas J, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. 2017; 72: 544–554.
- 29Necchi A, Raggi D, Gallina A, Ross JS, Farè E, Giannatempo P, et al. Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer. Eur Urol. 2020; 77: 701–710.
- 30Nomura S, Suzuki Y, Akatsuka J, Endo Y, Shimizu A, Hamasaki T, et al. Expression of epithelial-mesenchymal transition related markers in plasmacytoid urothelial carcinoma of the urinary bladder. BMC Urol. 2020; 20: 72.
Citing Literature
